Ключевые слова
Как цитировать
Аннотация
Применение ингибиторов тирозинкиназы (ИТК) в неоадъювантном режиме и использование реконструктивных методов в хирургической практике может расширить показания для использования хирургических методик в лечении пациентов с местно-распространенным немелкоклеточным раком легкого (НМРЛ), содержащим мутации EGFR.
Библиографические ссылки
Hishida T., Yoshida J., Aokage K. et al. Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases. Gen Thorac Cardiovasc Surg. 2016;7:429–33.
Levchenko E. et al. Down-Staging of EGFR Mutation-Positive Advanced Lung Carcinoma with Gefitinib Followed by Surgical Intervention: Follow-Up of Two Cases. Onkologie 2009;32:674–677.
Gomez D.R., Blumenschein G.R. Jr, Lee J.J. et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung.
Sakanoue I. et al. Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib. J Thorac Dis. 2018 Mar;10(3):E170-E174.
Kappers I., Klomp H.M., Burgers J.A. et al. Neoadjuvant (induction) erlotinib response in stageIIIA non-small-cell lung cancer. J Clin Oncol. 2008;26:4205–7.
Mok T.S., Wu Y.L., Thongprasert S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361:947-957.
Hishida T., Nagai K., Mitsudomi T. et al. Japan clinical oncology group. Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. J Thorac Cardiovasc Surg. 2010;140:e69–71.
Takamochi K., Suzuki K., Sugimura H. et al. Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation. Lung Cancer. 2007;58:149–55.
Shen H., Zhong X., Ge X.Q. et al. Surgical resection of lung adenocarcinoma without EGFR mutation after neoadjuvant gefitinib treatment. Clin Respir J. 2010;4:192–3.
Hashimoto K., Horinouchi H., Ohtsuka T. et al. Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer. Gen Thorac Cardiovasc Surg. 2012;60:851–4.
Marech I., Vacca A., Gnoni A. et al. Surgical resection of locally advanced epidermal growth factor receptor (EGFR) mutated lung adenocarcinoma after gefitinib and review of the literature. Tumori. 2013;99:e241–4.
Lara-Guerra et al. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer. J Clin Oncol. 2009 Dec 20;27(36):6229-36.
Schaake et al. Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J Clin Oncol. 2012 Aug 1;30(22):2731-8.
Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.
© АННМО «Вопросы онкологии», Copyright (c) 2021